Myasthenia gravis （MG） is a highly prevalent disorder of neuromuscular junction （NMJ） transmission and is mainly caused by blockage of the transmission of acetylcholine receptors and muscle-specific receptor tyrosine kinase by the NMJ， immune system disorders， and genetic factors. MG patients have the cardinal symptoms of skeletal muscle weakness， abnormal fatigue， and breathing or swallowing difficulties in severe cases， which can be life-threatening. MG can affect individuals of all ages， often with a long and complex treatment process. With the increasing understanding of this disease， great achievements have been made in its diagnosis and treatment， especially pharmacotherapy. The main treatment methods for MG include cholinesterase inhibitors， adrenal glucocorticoids， immunosuppressants， and thymectomy， and the treatment methods for MG crisis include immunoglobulin， plasma exchange， immune adsorption， new plasma exchange techniques， and assisted mechanical ventilation. With the advances in the types of drugs， more considerations have been given to the selection of drugs in clinical practice， such as economic capability， disease severity， durability of treatment efficacy， and severity of adverse events. This review introduces related drugs in terms of mechanism of action， main indications， methods of use， and adverse reactions， in order to select drugs that are more suitable for disease conditions. This review also introduces several other drugs that may have a certain therapeutic effect on MG， especially the new drugs with good efficacy in clinical treatment， such as targeted biologics and complement inhibitors. This review aims to help clinicians select proper therapeutic drugs and alleviate pain in patients， and it also provides the future directions for drug research and development.